Filter
26
Text search:
vector-based
vaccine
Featured
Recommendations
5
New Publications
2
Language
Document type
Guidelines
10
Fact sheets
5
No document type
3
Studies & Reports
2
Videos
2
Manuals
1
Training Material
1
Brochures
1
Resource Platforms
1
Countries / Regions
East and Southern Africa
2
West and Central Africa
2
Guinea
1
India
1
South Sudan
1
Germany
1
Ukraine
1
Chile
1
Latin America and the Carribbean
1
Russia
1
Authors & Publishers
Publication Years
Category
Countries
7
Clinical Guidelines
2
Capacity Building
1
Toolboxes
COVID-19
16
Refugee
4
Ebola & Marburg
3
Conflict
1
Zika
1
TB
1
Pharmacy
1
Published:February 02, 2021DOI:https://doi.org/10.1016/S0140-6736(21)00234-8
6 June 2022
These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included
...
(Первинна та бустерна вакцинації) – з векторною вакциною – (вакцина Janssen® від COVID-19 виробництва Janssen Cilag International/Johnson & Johnson
Станом на: 14 лютого 2022 р. (даний інформаційн
...
– векторною вакциною – (Janssen® від COVID-19 виробництва Janssen Cilag International/Johnson & Johnson)
Anamnese zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit Vektor-Impfstoff – (COVID-19
...
Available in English, German, French and Italian
Learn about the composition and delivery mechanism for the new classes of COVID-19 vaccines based on adenovirus from Johnson & Johnson and AstraZeneca with Dr. Jonathan Genzen, COO of ARUP Laboratories and an Associate Professor at the University of Utah School of Medicine.
The Committee examined the clinical development of Ebola virus vaccines and conducted an inventory of available data on their safety. It also reviewed 3 generic issues: updating a global strategy on vaccine saf
...
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the b
...
the Lancet : Published Online July 31, 2015 http://dx.doi.org/10.1016/S0140-6736(15)61117-5
AstraZeneca-SKBio in South Korea and Serum Institute of India
This document provides guidance on interventions to prevent vaccine-preventable disease outbreaks in the context of mass population movement resulting from the ongoing crisis in Ukraine.
first issued 18 August 2022
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence s
...
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and a
...
Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed
to support decision making. A countrywide mass vaccination campaign with the
use of
...
22 December 2020
The COVID-19 vaccine safety guidance manual has been developed upon recommendation and guidance of GACVS members, as well as by experts incorporating current and available information critical to all stakeholders when COVID-19 vac
...
The report presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.
